• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    New Local Data in GSK and IQVIA's Vaccine Track Supports Smarter Public Health Action at the Community Level

    10/1/25 10:00:00 AM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GSK alert in real time by email
    • New analysis of metro-area data reveals wide variation in adult vaccination trends across the US and points to opportunities for local action
    • Originally launched in 2022, Vaccine Track remains the only publicly accessible source for month-by-month immunization trends across a variety of adult vaccines, enabling analyses that could uncover possible drivers
    • Vaccine Track can help public health organizations and providers identify gaps and better target their efforts

    GSK plc (LSE/NYSE:GSK) today announced a major update to Vaccine Track, a first-of-its-kind, interactive public data tool for tracking adult immunization activity in the US. Users can now explore vaccination trends across 387 different metro areas* to get insights on adult immunization at the local level. Vaccine Track now also includes a full decade of data, providing a longer look at adult vaccination trends over time. Previously, the site focused on state and national data from 2019 onward. New month-by-month and geographic data are added to the site each quarter.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250930114016/en/

    Vaccine-preventable diseases impose a significant economic and health burden. In the US alone, they cost up to $9 billion annually in direct medical costs and productivity losses—80% of which is linked to unvaccinated adults.1 The most recent Centers for Disease Control & Prevention (CDC) data indicated that less than a quarter of US adults were up to date on all their recommended vaccinations as of 2022.2

    Leonard Friedland, VP and Director, Scientific Affairs and Public Health, Vaccines, GSK, said: "By adding metro-level data, Vaccine Track makes it clear where adult vaccination is seeing progress and where barriers persist. These insights could help guide public health partners on where to focus their attention so that all Americans have the opportunity to access vaccines and make informed decisions about their health."

    The new metro-level data launches alongside Vaccine Track's Q1 2025 insights, which reveal wide variation in adult vaccination across communities. While most metro areas experienced increases in Q1 2025 compared to Q1 2024, approximately one in five experienced a decline, indicating opportunities to explore the reasons behind this divergence.

    Delving into demographic, policy and healthcare delivery differences across metro areas could potentially help uncover the specific drivers behind adult vaccination trends. The ultimate goal is to support public health stakeholders aiming to increase vaccine uptake.

    To explore the tool, view the latest insights and subscribe to quarterly email updates, visit www.vaccinetrack.com.

    *Vaccine Track defines metro areas according to the US Census Bureau's concept of Metropolitan Statistical Areas (MSAs), which group cities and surrounding counties with a high degree of social and economic integration. The tool also contains data from less populated areas that don't fall into an established metro area.

    About Vaccine Track

    Originally launched in 2022, Vaccine Track is the first and only comprehensive public data tool designed to provide insights into adult vaccination trends across the US. Its mission is to empower public health leaders, policymakers, providers and individuals with transparent, up-to-date data that can inform immunization decisions and promote healthier communities.

    With its intuitive, interactive dashboards, Vaccine Track enables users to explore geographic and month-by-month trends across different vaccine types, demographics, payers and points of access. New data and insights are added to the site quarterly.

    Vaccine Track measures vaccinations in the form of medical and pharmacy claims for adults ages 19 and older for all tracked vaccines, but it's important to recognize that not all vaccines are indicated or recommended for all adults. GSK does not promote or endorse the use of any vaccine beyond its FDA-approved indication(s) or CDC recommendations. Patients should consult with their health care provider about what vaccines they may need.

    Vaccine Track is open to public and private stakeholders, welcoming the opportunity to potentially integrate and host additional data and viewpoints on adult vaccination trends. Data integration is subject to a Data Licensing Agreement.

    About GSK

    GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

    Cautionary statement regarding forward-looking statements

    GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2024, and GSK's Q2 Results for 2025.

    Registered in England & Wales:

    No. 3888792

    Registered Office:

    79 New Oxford Street

    London

    WC1A 1DG

    References

    1 Ozawa S, et al. Modeling the economic burden of adult vaccine-preventable diseases in the United States. Health Affairs. 2016 Nov 1;35(11):2124-32.

    2 CDC. Vaccination Coverage among Adults in the United States, National Health Interview Survey, 2022. October 4, 2024. Available at: https://www.cdc.gov/adultvaxview/publications-resources/adult-vaccination-coverage-2022.html

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250930114016/en/

    GSK inquiries

    Media:

    Kathleen Quinn

    +1 202 603 5003

    (Washington DC)

    Alison Hunt

    +1 540 742 3391

    (Washington DC)

    Investor Relations:

    Jeff McLaughlin

    +1 215 751 7002

    (Philadelphia)

    Frannie DeFranco

    +1 215 751 3126

    (Philadelphia)

    Get the next $GSK alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GSK

    DatePrice TargetRatingAnalyst
    6/3/2025Buy → Hold
    Berenberg
    4/15/2025$35.25Neutral
    Exane BNP Paribas
    2/12/2025Equal-Weight
    Morgan Stanley
    11/15/2024Buy → Hold
    Deutsche Bank
    11/12/2024$53.00 → $39.50Buy → Hold
    Jefferies
    10/31/2024Buy → Neutral
    Guggenheim
    7/8/2024Buy → Neutral
    UBS
    5/30/2024$47.00Neutral
    Goldman
    More analyst ratings

    $GSK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    New Local Data in GSK and IQVIA's Vaccine Track Supports Smarter Public Health Action at the Community Level

    New analysis of metro-area data reveals wide variation in adult vaccination trends across the US and points to opportunities for local action Originally launched in 2022, Vaccine Track remains the only publicly accessible source for month-by-month immunization trends across a variety of adult vaccines, enabling analyses that could uncover possible drivers Vaccine Track can help public health organizations and providers identify gaps and better target their efforts GSK plc (LSE/NYSE:GSK) today announced a major update to Vaccine Track, a first-of-its-kind, interactive public data tool for tracking adult immunization activity in the US. Users can now explore vaccination trends acros

    10/1/25 10:00:00 AM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Multiple Myeloma Research Foundation Unites Patients and Advocates to Hike New Hampshire's White Mountains to Accelerate a Cure for Multiple Myeloma

    NORWALK, Conn., Oct. 01, 2025 (GLOBE NEWSWIRE) -- The Multiple Myeloma Research Foundation® (MMRF®) today announced that a team of hikers, including multiple myeloma patients and advocates, will take on the rugged trails of New Hampshire's White Mountains as part of the Moving Mountains for Multiple Myeloma® (MM4MM) program. Sponsored by GSK plc (LSE/NYSE:GSK), the trek aims to raise awareness of multiple myeloma and generate critical funds to accelerate a cure for multiple myeloma. The hike will take place October 5 – 9, 2025. "Now in its ninth year, MM4MM has made tremendous progress and united hundreds of patients, caregivers, and supporters to raise funds that go directly to advancing

    10/1/25 7:00:00 AM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hengrui Pharma and GSK enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology

    Includes license for potential best-in-class PDE3/4 inhibitor (HRS-9821) in clinical development for treatment of COPDAdditional 11 programmes to be developed by Hengrui Pharma and optioned by GSK following phase I completionJIANGSU, China, July 27, 2025 /PRNewswire/ -- Hengrui Pharma (600276.SH; 01276.HK) today announced it has entered into agreements with GSK plc (LSE/NYSE:GSK) to develop up to 12 innovative medicines, adding significant value to the globalization strategy of Hengrui and significant new growth opportunities to GSK beyond 2031. The programmes were selected to complement GSK's extensive Respiratory, Immunology & Inflammation (RI&I) and Oncology pipeline, and assessed for the

    7/27/25 9:53:00 PM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GSK
    SEC Filings

    View All

    SEC Form 6-K filed by GSK plc

    6-K - GSK plc (0001131399) (Filer)

    10/1/25 10:10:01 AM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by GSK plc

    6-K - GSK plc (0001131399) (Filer)

    10/1/25 7:53:31 AM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by GSK plc

    6-K - GSK plc (0001131399) (Filer)

    9/30/25 7:56:14 AM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GSK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    GlaxoSmithKline downgraded by Berenberg

    Berenberg downgraded GlaxoSmithKline from Buy to Hold

    6/3/25 7:26:51 AM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Exane BNP Paribas initiated coverage on GlaxoSmithKline with a new price target

    Exane BNP Paribas initiated coverage of GlaxoSmithKline with a rating of Neutral and set a new price target of $35.25

    4/15/25 12:40:46 PM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley initiated coverage on GlaxoSmithKline

    Morgan Stanley initiated coverage of GlaxoSmithKline with a rating of Equal-Weight

    2/12/25 7:05:11 AM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GSK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: GLAXOSMITHKLINE PLC converted options into 700,772 units of Common Stock and bought $4,950,000 worth of Common Stock (275,000 units at $18.00)

    4 - GLAXOSMITHKLINE PLC (0001131399) (Reporting)

    7/6/21 4:38:14 PM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by GLAXOSMITHKLINE PLC

    3 - GLAXOSMITHKLINE PLC (0001131399) (Reporting)

    7/6/21 4:22:59 PM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: GLAXOSMITHKLINE PLC converted options into 30,253,189 units of Common Stock

    4 - GLAXOSMITHKLINE PLC (0001131399) (Reporting)

    6/23/21 6:14:59 PM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GSK
    Leadership Updates

    Live Leadership Updates

    View All

    GSK and Lifetime® launch original movie to raise awareness about the impact of meningitis

    Pretty Hurts, a new Lifetime Original Movie brought to you by GSK, informs Lifetime's mom audience about meningococcal disease, known as meningitis Partnership is part of GSK's Ask2BSure campaign, which encourages parents of teens and young adults ages 16-23 to start a conversation with their teen's doctor about meningitis and vaccination Hollywood moms of teens, Alyson Hannigan and Sarah Michelle Gellar, team up with GSK and Ask2BSure to help raise awareness GSK plc (LSE/NYSE:GSK) today announced its sponsorship of Pretty Hurts, a gripping new Lifetime Original Movie and the latest extension of GSK's Ask2BSure public health campaign. Premiering on June 28, 2025, at 8 p.m. ET/7 p.m.

    5/9/25 9:00:00 AM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GeminiBio Appoints Mike Stella to Board

    Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

    2/18/25 9:00:00 AM ET
    $AMGN
    $GSK
    $JNJ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer

    TORONTO and PHILADELPHIA, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd (NASDAQ:MDCX, TSXV:MDCX) (the "Company") is pleased to announce the appointment of Faisal Mehmud, MD as Chief Medical Officer. "We are thrilled to welcome Dr. Mehmud to our leadership team," stated Dr. Raza Bokhari, Exec. Chairman & CEO. "Faisal has a proven track record in integrating cutting-edge science with practical, evidence-based medical strategies to develop partnerships and launch high impact therapies. We aim to capitalize on his experience and expertise to expand our drug development pipeline and foster collaboration with strategic partners to bring to market our novel non-invasive patented dissolvab

    11/18/24 7:30:00 AM ET
    $GSK
    $MDCX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GSK
    Financials

    Live finance-specific insights

    View All

    Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%

    Highlights Second quarter revenue grew 15% year-over-year to $212 million, driven by Prenatal (25%), Pharmacogenomics (22%), and Hereditary Cancer (19%).Second quarter GAAP earnings per share improved to $(0.41) from $(1.42) in the second quarter of 2023; adjusted earnings per share improved to $0.05 from $(0.08) in the second quarter of 2023.Increasing 2024 financial guidance with full year revenue moving to a range of $835 - $845 million, or an annual growth rate of between 11% and 12%, and increasing adjusted earnings per share (EPS) to a range of $0.08 - $0.12.1 _________________________1 The company does not forecast GAAP EPS because it cannot predict certain elements that are include

    8/6/24 4:05:00 PM ET
    $GSK
    $MYGN
    $PSNL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Medical Specialities

    GSK and CureVac to Restructure Collaboration into New Licensing Agreement

    GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinationsCureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replacedLONDON, UK, TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 3, 2024 / GSK plc (NYSE:GSK) and CureVac N.V. (NASDAQ:CVAC) today announced they have restructured their existing collaboration into a new licensing agreement, allowing each company to prioritize investment and focus their respective mRNA

    7/3/24 2:40:00 AM ET
    $CVAC
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    23andMe Reports Third Quarter Fiscal 2024 Financial Results

    SOUTH SAN FRANCISCO, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics and biopharmaceutical company, reported its financial results for the third quarter of fiscal year 2024 (FY24), which ended December 31, 2023. Key Results Reported total revenue of $44.7 million in the third quarter of fiscal 2024, compared to $66.9 million in the third quarter of fiscal 2023, a decrease of approximately 33% due to lower research revenue after the conclusion of the GSK collaboration exclusivity term in July 2023 and lower PGS kit volumes.Announced a non-exclusive data license with GSK plc (NYSE:GSK) for novel drug target discovery and other research. U

    2/7/24 4:01:00 PM ET
    $GSK
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GSK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by GSK plc

    SC 13G/A - GSK plc (0001131399) (Subject)

    11/12/24 4:32:59 PM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by GSK plc (Amendment)

    SC 13G/A - GSK plc (0001131399) (Subject)

    2/13/24 1:37:25 PM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by GSK plc (Amendment)

    SC 13G/A - GSK PLC (0001131399) (Subject)

    2/14/23 1:54:01 PM ET
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care